Galapagos NV, a European biopharmaceutical company, has made significant strides in the development of medicines for high unmet medical needs. With a robust pipeline of products, the company aims to tackle a range of conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, uveitis, relapsed/refractory non-Hodgkin lymphoma, and chronic lymphocytic leukemia. The company's lead product filgotinib, a JAK1 inhibitor, is in the advanced stages of clinical trials for rheumatoid arthritis, with promising results. Filgotinib is also being explored for its potential to treat other inflammatory conditions. Galapagos NV's pipeline also comprises GLPG3667, which has completed Phase 1b trials, and GLPG5101 and GLPG5201 - CD19 CAR-T product candidates that are manufactured at point-of-care and are currently in Phase I/II trials for relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The Mechelen, Belgium-based company has secured collaboration agreements with industry heavyweights Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG. Founded in 1999, Galapagos NV has established itself as an integrated biopharmaceutical company that focuses on innovative drug discovery, development, and commercialization. With its diverse pipeline of products, the company is poised to make an indelible impact on the biotech landscape.
Galapagos's ticker is GLPG
The company's shares trade on the NASDAQ stock exchange
They are based in Mechelen, Belgium
There are 501-1000 employees working at Galapagos
It is glpg.com/who-are-we
Galapagos is in the Healthcare sector
Galapagos is in the Biotechnology industry
The following five companies are Galapagos's industry peers: